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Abstract 
Background: In colon cancer, appropriate tumour excision and associated 
lymphadenectomy directly impact recurrence and survival outcomes. Currently, there is 
no standard for mesenteric lymphadenectomy, with a lymph node yield of 12 acting as a 
surrogate quality marker. Our goal was to determine the safety and feasibility of 
Indocyanine green (ICG) fluorescence imaging to demonstrate lymphatic drainage in 
colon cancer in a dose-escalation study. 
Methods: A prospective pilot study of colon cancer patients undergoing curative 
laparoscopic resection was performed. At surgery, peritumoural subserosal ICG injection 
was done to demonstrate lymphatic drainage of the tumour. A specialized fluorescence 
system excited the ICG and assessed lymphatics in real-time. The primary outcome was 
the feasibility of ICG fluorescent lymphangiography for lymphatic drainage in colon 
cancer. Secondary outcomes were the optimal protocol for dose, injection site, and ICG 
lymphatic mapping timing. 
Results: Ten consecutive patients were evaluated (6 males, mean age 69.5 years). In all, 
lymphatic channels were seen around the tumour to a varying extent. Eight (80%) had 
drainage to the sentinel node. In all cases where the lymphatic map was seen, there was 
no further spread 10 minutes after injection. Factors contributing to reduced lymphatic 
visualisation were inadequate ICG concentrations, excess India ink blocking drainage, 
and inflammation from tattoo placement.  
Conclusions: ICG can be safely injected into the peritumoural subserosa and demonstrate 
lymphatic drainage in colon cancer. This proof of concept and proposed standards for the 
procedure can lead to future studies to optimize the application of image-guided precision 
surgery in colon cancer. 
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Introduction 
Surgical management of colon cancer must address the risk of both local and distant 
disease recurrence. Currently, there is no standard of care for mesenteric 
lymphadenectomy, which directly influences the risk of distant failure and adjuvant 
treatment decisions. Lymph node yield acts as a surrogate marker for appropriate 
oncological surgery and procuring a minimum of 12 nodes is recommended by several 
international guidelines [1,2].  The number of nodes retrieved from the surgical specimen 
improves accuracy of prognosis and influences survival outcomes in patients with colon 
cancer [3–5].  
Complete mesocolic excision (CME) has been advocated to increase the nodal yield and 
consequently improve survival outcomes [3–5]. However this approach   is controversial 
and while the potential to improve cancer outcomes is stimulating, there is potential 
serious morbidity associated with the radical mesocolic excision, and insufficient 
consistent, high quality evidence to date to recommend widespread adoption of CME or 
resecting more nodes, in general [6–8]. Performing a more precise lymphadenectomy and 
resection may be a better option for overall patient outcomes. 
Fluorescence imaging (FI) is a tool that that could be used to guide lymphatic mapping 
and a more precise, oncologic resection. Pairing peritumoural injection of ICG with FI 
lymphangiography could highlight drainage from the primary tumour within the 
mesentery, demonstrating the precise margins and involved nodes. The purpose of this 
pilot study was to determine the safety and feasibility of indocyanine green (ICG) 
fluorescence imaging for intraoperative localization of the primary tumour, lymphatic 
drainage and sentinel node mapping in colon cancer. Our hypothesis was that ICG 
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fluorescence imaging would be safe, feasible, and successfully demonstrate the 
intraoperative localization of the primary tumour, its lymphatic drainage, and sentinel 
node map in colon cancer. 
Materials and methods  
Study design and patient population 
This dose-escalation study received approval from the Joint Research Office, University 
College London Hospital. For this pilot study, 10 consecutive patients with colon cancer 
were prospectively identified from the colorectal cancer multidisciplinary team (MDT) 
conference at a single tertiary referral. Patients were eligible for enrollment if they over 
18 years of age; diagnosed with primary colon cancer proximal to the rectosigmoid 
junction (confirmed by lower endoscopy and computed tomography (CT) imaging); able 
undergo routine staging with intravenous contract enhanced CT scan and tolerate 
mechanical bowel preparation for surgery; and scheduled for curative surgical resection 
of the cancer. Patients were excluded if, under 18, or presenting with a bowel obstruction; 
undergoing an emergent/ urgent resection or surgery for palliative intent; if they had 
distant metastases; an allergy or history of adverse reaction to ICG, iodine or iodine dyes; 
hepatic dysfunction with a MELD Score > 10; or renal dysfunction with a Creatinine 
level over 2.0mg/dL. All patients had a preoperative work-up per standard of care, 
including a colonoscopy with tissue biopsy confirming adenocarcinoma of the colon, 
staging for distant metastatic disease with a CT scan of the chest, abdomen and pelvis, 
and presentation at the multidisciplinary team (MDT) meeting to guide management.   
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Technique 
Tumours were marked with India ink at the time of the index colonoscopy to assist 
intraoperative identification. Surgical resection was performed within 4 weeks of 
diagnosis. All cases were performed by a single colorectal surgeon through a multiport 
laparoscopic approach. The laparoscopic procedure was carried out as per routine. 
Following ligation of the main vascular pedicle (the ileocolic artery or inferior 
mesenteric/ascending left colic artery) and mobilization of the colon, the specimen was 
extracorporalized through a small midline incision using a wound retractor. 
Intraoperative ICG injection was then administered as the study intervention. A 1mL 
subserosal injection of ICG was placed in 4 sites around the tumour (4mL in total) 
(Figure 1). Great care was taken not to spill ICG during this process, as it would ruin the 
surgical field when it was made to fluoresce. An alcohol swab was used to wipe the 
surface of the bowel following each injection. The concentration of ICG was varied from 
5mg/10mL, 5mg/5mL, and 5mg/3mL. Using commercial laparoscopic fluorescence 
camera systems (Pinpoint™, Novadaq, Mississauga, Ontario, Canada and AIM 1588TM, 
Stryker, Kalamazoo, Michigan, USA), the ICG was excited by light in the near infrared 
(NIR) spectrum, for image comparison in standard white light and NIR, and real-time 
visualisation of the lymphatic drainage. The main outcome measure was the feasibility of 
ICG to identify lymph node drainage. Secondary outcomes included defining the optimal 
protocol for dose, injection site, and timing for ICG lymphatic mapping. 
 
Patient and tumour demographics, operative, and lymphangiographic procedural details 
were assessed. Data points evaluated included the age, gender, preoperative staging, 
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procedure performed, level of anastomosis, if the tumour was localised with ICG, if the 
ICG localization was consistent with the preoperative imaging, if there was visualisation 
of the lymphatic drainage, the time to central lymph node visualisation, the presence of 
lymph nodes outside the proposed mesenteric resection, the pathologic stage, the number 
of lymph nodes procured, the number of positive lymph nodes, and the presence of 
positive resection margins. Descriptive statistics were used to describe the outcomes, 




Ten consecutive patients with a diagnosis of colon cancer undergoing curative resection 
between March 2017 and June 2017 at University College London Hospitals were 
enrolled in the study and evaluated. The mean patient age was 69.5 years (SD ±7.13). 
There were 6 males and 4 females. The tumour distribution in the colon was 7 (70%) 
ascending, 2 (20%) sigmoid, and 1 (10%) descending. All patients had biopsy-proven 
adenocarcinoma, of which 70% were preoperatively staged as T3 (30% were T1 or T2) 
and 10% as N1/N2 (the remainder were N0). All patients had a preoperative computed 
tomography (CT) scan for staging. No patient had CT-demonstrable distant metastases, 
and none received neoadjuvant chemotherapy. The demographic data and tumour stage is 
presented in Table 1.  
 
Procedural details are listed in Table 2. The procedures performed were a right 
hemicolectomy (n=7, 70%), a sigmoid colectomy (n=2, 20%) and a left hemicolectomy 
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(n=1,10%). All procedures were performed laparoscopically as curative, restorative 
resections, with 7 ileocolic anastomoses and 3 colo-colonic anastomoses. There were no 
intraoperative conversions to open laparotomy. 
 
The ICG was injected into the subserosal layer after extracorporealisation, as described in 
the methods. The optimal concentration of ICG was 5mg/10mL. The primary tumour was 
localised in all patients within 60 seconds (Figure 2). The ICG localization was consistent 
with the preoperative imaging in 8 of 10 patients (80%). Lymphatic drainage was 
variably demonstrated in all 10 patients (100%) (Figure 3). In 7 of 10 (70%), there was 
complete drainage visible - a vibrant and clearly visible map from the tumor across the 
mesenteric lymphatics to the nodes. In the remaining 3 (30%) patients, there was partial 
demonstration- an incomplete map of the mesenteric lymphatics between the tumor and 
the nodes of lymphatic drainage, which was not sufficient to guide a lymphadenectomy. 
Eight patients (80%) had ICG drainage to the sentinel node demonstrated. The mean time 
to central lymph node visualisation was 4.32 minutes (SD±1.45). The optimal timing to 
demonstrate lymphatic drainage was 10 minutes, after which no further lymphatics were 
visualised. In 2 patients (20%), additional or aberrant lymph nodes located outside of the 
proposed resection margins were demonstrated. These nodes would not have been 
visualised without ICG FI; here, the ICG was preferentially held in these aberrant nodes 
and showed significant central intensity of signal. Furthermore, these nodes would have 
been outside the standard resection margins one would expect to follow for each case and 
not included in the planned resection or routine lymphadenectomy. In one patient the 
node was located in the mesentery adjacent to the Hemolok clip on the ileocolic artery. 
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This node was not readily palpable but clearly visible on all 3 modes of imaging. In this 
case the mesenteric resection was extended to safely include the node and there was no 
need to perform a more proximal ligation of the vessel. As the mesenteric 
lymphadenectomy had not been completed it was possible to make this change without 
needing to perform a more complex dissection. In the second case, the visible node was 
found to be outside the planned resection margin but was safely included in the resection 
by taking additional mesenteric tissue at this margin. In both cases, there was no need to 
perform a more radical dissection(Figure 4). In both patients, these nodes were positive 
on histopathology.  
 
Overall, the median lymph node yield was 22 (range, 14-49 nodes), and the median 
positive lymph nodes were 2 (range, 0-8) nodes. Final pathological staging was 30% 
Stage II (n=3), 30% Stage III (n=3), and 40% Stage IV (n=4). There were no positive 
resection margins. No intraoperative or injection-related adverse effects occurred with 
30-day follow-up. Procedural and pathologic details are listed in Table 3.  
 
Factors noted that may have contributed to lack of lymphatic identification were 
inadequate concentrations of ICG, excess India ink (from the endoscopic tattoo) blocking 
lymphatic drainage, and inflammation around the tumour from tattoo placement. No 
intraoperative or injection-related adverse effects occurred with 30-day follow-up. 
 
DISCUSSION 
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The results of the present study show that FI using ICG can variably demonstrate 
draining lymphatic vessels in colon cancer. Factors including tumour reaction and 
inflammation, excess India ink used to localise the tumour and inadequate ICG 
concentration may contribute to suboptimal visualisation. This novel approach to 
demonstrate tumour lymphatics has the potential to guide mesenteric lymphadenectomy 
in colon cancer.  
 
Currently, there is no standard of care for resection of colon cancer, with the bone of 
contention being the extent of the mesenteric lymphadenectomy. CME attempts to 
translate the concept of the intact ‘package’ of the tumour and its main lymphatic 
drainage proposed by Heald into total mesorectal excision (TME) for optimal rectal 
cancer surgery [9,10]. With the increased mesocolon and number of nodes resected, 
proponents of the technique claim improved oncologic outcomes compared with 
conventional colon resection [3]. However, there is additional morbidity associated with 
CME, and no conclusive evidence for its oncologic benefit [6–8].  
 
Performing a more precise, patient-specific lymphadenectomy and tumour resection is an 
alternative to CME. Lymphatic mapping allows a focused review of the lymph nodes, 
helping to identify those most likely to harbour metastases, which can improve the 
staging and stratification for adjuvant treatment [11]. ICG FI has the potential to guide 
resection by identifying the tumour, lymphatic map, and involved nodes in real time, 
possibly allowing the surgeon to adjust the resection margins and ensure all oncologically 
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relevant tissue is removed with precise mesocolic margins, instead of performing a 
radical CME. Intraoperative lymphangiography could also help establish the lymphatic 
drainage for tumours with a variable course or in cases of reoperation where lymphatic-
bearing tissue has been excised [12,13].   
 
ICG has many different uses in gastrointestinal surgery [14], and specifically, has been 
shown to effectively demonstrate perfusion within the bowel when injected intravenously 
[15–19].  Fluorescence lymphangiography has been previously described for sentinel 
lymph node detection in other cancers. The technique has been proven successful in 
breast, melanoma, penile, vulvar, oesophageal, gastric, and oral squamous cell cancers 
[20–27]. There only limited data available on the use of FI to demonstrate sentinel nodes 
in colorectal cancer [11,28–30]. The published studies found value for identifying 
sentinel and aberrant mesocolic lymph nodes; however, no standardized technique has 
been described and variable rates of accuracy, sensitivity, and specificity are reported. In 
our study, 80% of patients had drainage to the sentinel node demonstrated, with a mean 
time to central lymph node visualisation of 4.32 minutes. This rate of identification was 
similar to published results of 89% to 98% detection, with a false negative rate of 18-67% 
[31]. A recent systematic review of 12 studies including 248 patients reported pooled 
sensitivity and specificity rates were 71% and 84.6%, with median sensitivity, specificity, 
and accuracy rates of 73.7, 100, and 75.7% [32]. However the review included both colon 
and rectal cancer, and demonstrated the heterogeneity in reported data. The authors 
concluded that ICG is a promising technique for detecting sentinel nodes in colorectal 
cancer although its oncological utility remains unknown. 
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While the prognostic value of the sentinel node in colon cancer is still under debate, the 
lymphatic drainage may be a better marker for optimal resection, as this can help 
determine the ideal mesocolic resection margin, as well as change the operative course 
and recommendations for adjuvant therapy postoperatively. In the present study, we had 
visualisation of the lymphatic drainage in all patients. Earlier studies also described the 
safety, feasibility, and high success rate of ICG FI in this application [30,33,34]. In our 
sample, the lymphatic drainage was partially demonstrated in 3 patients, insufficient to 
guide the lymphadenectomy. From this, we established what variables likely impacted 
the success of the lymphatic mapping, including inadequate concentrations of ICG, 
excess India ink blocking lymphatic drainage, and inflammation around the tumour from 
tattoo placement. To our knowledge, no study to date has described factors likely to block 
lymphatic uptake. One study by van der Pas et. al., described factors which may 
contribute to false-negative findings, including large tumour size, drainage to adjacent 
lymphatic vessels, and the use of a rigid needle [29]. These pearls may help others 
through roadblocks in fluorescence lymphangiography. 
 
A further benefit of real-time intraoperative ICG is identification of aberrant lymph 
nodes. In the present study, 2 patients had aberrant notes identified in NIR mode, and we 
changed the course of our mesocolic resection to include these nodes. In both cases, these 
nodes were positive on pathologic assessment; without the ICG lymphangiography, these 
positive nodes would not have been included in the standard resection as they were not 
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immediately palpable, which could have impacted the oncologic outcomes of the 
patients. ICG lympangiography helps provide a real-time anatomical model for the 
lymphatics which may lead to more precise oncological resections. Prior work has 
supported the value of ICG FI to identify aberrant nodes [28,30,35–37].  In a series of 18 
patients, Cahill et. al. found 4 patients had fluorescing sentinel nodes outside the planned 
resection field [34]. In 21 patients undergoing laparoscopic resection for colorectal 
cancer, Nishigori et. al. reported ICG FI lymph node mapping led to 23.5% of patients 
requiring modifications in the extent of lymphadenectomy, and 16.7 % required a change 
in the intestinal resection plan [30]. Thus, the improved visualisation of involved lymph 
nodes in real-time afforded by the ICG FI compared to white light could improve the 
oncologic resection and outcomes. 
 
This work adds unique aspects to the literature in that the technique is detailed to 
standardize the protocol for future work, including the ideal site for injection, dosage, and 
concentration. In this study, we had successful identification of the primary tumour from 
peritumoural injection into the subserosal space using 1mL of ICG solution (5mg/10mL) 
in all patients. The ICG localization was consistent with pre-operative imaging in 8 of our 
10 patients, showing potential value for localization, especially in laparoscopic cases, 
where there is no tactile sense. Published work has wide variations in the ICG 
concentrations (0.5, 2.5, 5 mg/mL), dosage (0.2-5 mL), site of ICG injection 
(submucosal, subserosal, both submucosal and subserosal, or intravenous) and the timing 
of the injection (preoperative, intraoperative, or both pre- and intraoperative) 
[22,26,29,30,33,34,38–41].  We have previously reported our technique of subserosal 
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injection to visualize lymphatic drainage in a colon cancer patient [12]. The choice of the 
subserosal injection site was supported by van der Pas et. al., who found it was more 
effective, especially with a flexible tip needle.  Watanabe et. al. used a submucosal 
injection site, which was associated with lower rates of tumour identification [42]. The 
authors described 93.8% visibility of the tumour intraoperatively after a submucosal 
injection of 0.5 mL of ICG (2.5 mg/mL) during colonoscopy, with significantly better 
visibility after an interval of < 7 days between injection and surgery than after ≥10 days 
[42]. In a previously published work we injected the Establishing best practice can help 
reduce variability in future work. 
 
We recognize some limitations of this study. The study design was a pilot for safety and 
feasibility. Thus, a small sample was used with no comparison group. In addition, a 
single surgeon at a single centre performed all cases, which could limit the 
generalizability of the results. However, demonstrating the ideal protocol, safety and 
feasibility, as well as potential benefits supports further work on ICG lymphatic mapping 
for defining the resection margins and its impact on pathological staging.   
 
Conclusions 
Our results indicate that ICG fluorescence lymphangiography is safe and feasible for 
identifying the primary tumour, its lymphatic drainage, and potentially malignant nodes 
in colon cancer.  Most importantly, ICG fluorescent lymphangiography had benefit in 
identifying additional and aberrant positive lymph nodes outside of the standard resection 
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margins, which changed our operative plan. There is ongoing work looking at the utility 
of ICG to highlight malignant nodes, as this could have great implications for oncologic 
outcomes and guiding the surgical course. Further studies are needed to determine the 
value of this technique for more precise, oncologic resections in colon cancer. 
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Table 1: Patient and tumour details 
Variable n  
Age, years, (mean,±SD) 69.50 (±7.13) 
 Male/ Female (n,%) 4 (40%)/ 6 (60%) 
Tumour location (n,%)  
Ascending colon 7 (70%) 
Sigmoid colon 2 (20%) 
Descending colon 1 (10%) 
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Table 2: Procedural details 
Variable n (%) 
Procedure performed   
Laparoscopic Right hemicolectomy 5 (50%) 
Laparoscopic Left hemicolectomy 3 (30%) 
Laparoscopic Sigmoid colectomy 2 (20%) 
Stoma created?  1 (10%) 
Level of anastomosis   
Ileocolic 7 (70%) 
Colorectal 3 (30%) 
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Table 3: Protocol and pathologic details 
Variable n  
Tumour localised with ICG? (n,%) 10 (100%) 
ICG localization consistent with preoperative imaging? 
(n,%) 
8 (80%) 
Visualisation of lymphatic drainage?(n,%) 10 (100%) 
Time to central lymph node visualisation, minutes (mean 
±SD) 
4.32 (±1.45) 
Patients with lymph nodes identified with ICG outside of 
the proposed mesenteric resection margin? (n,%) 
2 (20%) 
Lymph node yield (median, range) 22 (14-49) 
Number of positive lymph nodes (median, range) 2 (0-8) 
Positive resection margins (n,%) 0  (0%) 
Surgical Pathology  (pTNM)  
Patient 1 T4b N2 M1 
Patient 2 T4 N2 M0 
Patient 3 T4b N2 M1 
Patient 4 T3 N0 Mx 
Patient 5 T1 N1 Mx 
Patient 6 T3 N0 Mx 
Patient 7 T3 N1 M1  
Patient 8 T4b N0 Mx 
Patient 9 T4b N1 M0 
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Figure legends 
Figure 1- Subserosal peritumoural injection of Indocyanine green 
Figure 2 – Demonstration of the primary colon tumour with indocyanine green 
fluorescence imaging 
Figure 3 – Demonstration of the lymphatic channels associated with a colon tumour using  
indocyanine green fluorescence imagingI 
Figure 4- Localization of an aberrant lymph node with indocyanine green fluorescence 
imaging; the node was outside of the standard resection margin, but was mesocolic 
excision was amended to include this node in the specimen. The node was positive on 
pathological assessment. 
 
 
 
 
 
 
 
 
 
